TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02098265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Assessments
Description: These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Assessments
Description: These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: A functional magnetic resonance image will be collected.
Study: NCT01879462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2878175
Description: Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2878175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2878175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2878175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2878175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2878175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Visually matching GSK2878175
Study: NCT02058511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthesia Premedication, Induction and Maintenance
Description: The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.~The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pupillometry after administration of anesthetic drugs
Description: All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.~Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period~The administered drugs are:~Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia.
Study: NCT00734604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil once a day [T(OaD)]
Description: 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil once a day [T(OaD)]
Description: 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil once a day [T(OaD)]
Description: 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil once a day [T(OaD)]
Description: 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil once a day [T(OaD)]
Description: 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil once a day [T(OaD)]
Description: 5 mg tablet taken once a day (OaD) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate as needed [S(PRN)]
Description: 100 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate as needed [S(PRN)]
Description: 100 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate as needed [S(PRN)]
Description: 100 mg tablet taken as needed (PRN) by mouth for 8 weeks
Study: NCT02098265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: A functional magnetic resonance image will be collected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: A functional magnetic resonance image will be collected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EEG
Description: EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
Study: NCT00734604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate as needed [S(PRN)]
Description: 100 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate as needed [S(PRN)]
Description: 100 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil citrate as needed [S(PRN)]
Description: 100 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil as needed [T(PRN)]
Description: 20 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil as needed [T(PRN)]
Description: 20 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil as needed [T(PRN)]
Description: 20 mg tablet taken as needed (PRN) by mouth for 8 weeks
Study: NCT00855920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Description: Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Indomethacin)
Description: Placebo (for Indomethacin) orally TID for 12 days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rilonacept)
Description: Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
Study: NCT04891874

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Radiation using stereotactic radiotherapy device.
Study: NCT02781493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
Description: Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
Study: NCT02098265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoveriX
Description: RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delay
Description: 10 week delay before intervention

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI-FES

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-FES
Study: NCT00734604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil as needed [T(PRN)]
Description: 20 mg tablet taken as needed (PRN) by mouth for 8 weeks
Study: NCT00687115

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Loss
Description: liquid diet at 50% of weight maintaining intake

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overfeeding
Description: Overfeeding at 150% of weight maintaining intake

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overfeeding Low Pro
Description: Overfeeding 150% of normal intake at \<5% protein
Study: NCT02098265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-FES
Study: NCT04023110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Individually dosed carvedilol
Study: NCT00734604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil as needed [T(PRN)]
Description: 20 mg tablet taken as needed (PRN) by mouth for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil as needed [T(PRN)]
Description: 20 mg tablet taken as needed (PRN) by mouth for 8 weeks
Study: NCT04164082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo bladder biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo urine and blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy
Description: Undergo cystoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given intravesically

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT
Study: NCT03656926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
Study: NCT04157101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The 12-session remote health coaching intervention assists Veterans in developing and maintaining health behaviors that meet their life goals. Veterans begin by discussing their symptoms, the impact of their symptoms, and their beliefs about Pain-CMI. Next, the Veteran identifies discrepancies between where they are and where they want to be for 5 lifestyle factors. The first half of treatment focuses on providing education about the 5 lifestyle factors. Veterans are introduced to behavior change/health coaching principles. The major focus is on behavior change and development of long-term healthy habits. During the last session, Veterans develop a long-term plan to maintain behavioral changes after the 12-week program and identify the skills that they can utilize moving forward.
Study: NCT02414776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: administration of hydroxychloroquine in combination with the current hormonal therapy
Study: NCT03469518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-Cx plus PS plus GOS

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: β-Cx plus PS
Study: NCT00788931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral LBH589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study: NCT00692614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
Study: NCT03174405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)
Study: NCT02781493

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 mg Placebo plus 2 L Polyethylene Glycol regimen
Description: Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
Study: NCT02650362

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Study: NCT01767155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108 / zoptarelin doxorubicin
Description: 267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
Study: NCT01622790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir 600 mg/lamivudine 300 mg
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir 600 mg/lamivudine 300 mg
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Study: NCT00310791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen/progestin)
Description: Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: Placebo (sugar pill)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA)
Description: 50 mg tablet, 1 daily
Study: NCT03851068

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldax Tria Aortic Valve
Description: Aortic Valve Replacement
Study: NCT00959621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: ASA 100 mg once daily per os

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klexane
Description: Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klexane and ASA
Description: Klexane 40 mgx 1 sc and ASA 100 mg po
Study: NCT04157101

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Psychotherapy
Description: Our control will be supportive psychotherapy which will focus on discussing weekly stressors in a supportive, non-directive way. Session content is patient-driven, and sessions focus on emphasizing the patients' strengths, following patients' emotional affect, and building a therapeutic alliance. Participants will be asked to generate the topic they would like to discuss for the session and will complete a worksheet between sessions noting emotional events throughout their week (A time when I felt stressed was . ) in order to help identify experiences for discussion in session. The control consists of 12 weekly sessions delivered via telephone or video and will be delivered by bachelor's, or master's level providers.
Study: NCT01032642

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device for hysterosalpingography
Description: a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
Study: NCT02141633

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiogram plus albuterol
Description: participants will performed echocardiogram before and 15 minutes after inhaled albuterol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiogram plus albuterol
Description: participants will performed echocardiogram before and 15 minutes after inhaled albuterol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: airway blood flow plus albuterol
Description: participants will performed echocardiogram before and 15 minutes after inhaled albuterol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: airway blood flow plus albuterol
Description: participants will performed echocardiogram before and 15 minutes after inhaled albuterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
Study: NCT03055325

Intervention type: OTHER
Intervention: Observational study of patients undergoing surgery
Description: Cognitive testing, testing of heart rate variability and collection of blood samples
Study: NCT00176488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Epirubicin (100 mg/m2) will be given on Day 1
Study: NCT04251117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNOS-PV02
Description: GNOS-PV02 delivered by intradermal injection and electroporation
Study: NCT01966900

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54gp140 mixed with GLA-AF
Description: Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54gp140 mixed with GLA-AF
Description: Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
Study: NCT03932110

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: omentin, visfatin
Description: diagnostic blood test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: omentin, visfatin
Description: diagnostic blood test

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: omentin, visfatin
Description: diagnostic blood test
Study: NCT03308877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI
Description: Four 45-minute, brief motivational sessions for substance use

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stadard Care (SC)
Description: Standard procedures at pretrial program + assessement
Study: NCT04251117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012
Description: INO-9012 delivered by intradermal injection and electroporation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered as an intravenous (IV) infusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA®2000 EP Device
Description: CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
Study: NCT03308877

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stadard Care (SC)
Description: Standard procedures at pretrial program + assessement
Study: NCT04258397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone vs. matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo
Study: NCT01877434

Intervention type: PROCEDURE
Intervention: Reversed shoulder arthroplasty
Study: NCT02322398

Intervention type: DRUG
Intervention: rFSH plus rLH
Description: 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
Study: NCT00176488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
Study: NCT01980836

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine